Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13343
Title: Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection.
Austin Authors: Angus, Peter W ;Richards, Michael J;Bowden, S;Ireton, J;Sinclair, R;Jones, R ;Locarnini, S
Affiliation: Victorian Liver Transplant Unit
Issue Date: 8-Jul-1993
Publication information: Journal of Gastroenterology and Hepatology; 8(4): 353-7
Abstract: The authors have successfully used combination ganciclovir and foscarnet chemotherapy to control viral replication following liver transplantation in a patient with severe recurrence of hepatitis B virus (HBV) infection. The disease was characterized by extremely high viraemias, deteriorating liver function, and high levels of intra-hepatic hepatitis B core antigen (HBcAg) and hepatitis B surface antigen (HBsAg). Treatment resulted in a greater than 30-fold reduction in serum HBV DNA and HBsAg levels. Liver function tests returned to normal and the histological progression of the disease was arrested. Hepatic cytoplasmic HBsAg decreased substantially but there was little change in HBcAg, implicating HBsAg rather than HBcAg in the liver injury. Combination antiviral chemotherapy using agents such as ganciclovir and foscarnet may offer a new approach to the management of post-transplant recurrence of HBV.
URI: https://ahro.austin.org.au/austinjspui/handle/1/13343
ORCID: 
Journal: Journal of Gastroenterology and Hepatology
URL: https://pubmed.ncbi.nlm.nih.gov/8374091
Type: Journal Article
Subjects: Adult
Drug Therapy, Combination
Foscarnet.administration & dosage
Ganciclovir.administration & dosage
Hepatitis B.drug therapy.immunology.pathology.surgery
Hepatitis B Antigens.analysis
Humans
Liver.immunology.pathology
Liver Transplantation
Male
Recurrence
Appears in Collections:Journal articles

Show full item record

Page view(s)

24
checked on Dec 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.